^
Association details:
| Biomarker: | ASXL1 mutation |
|---|---|
| Cancer: | Myelodysplastic Syndrome |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + azacitidine (DNMT inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Azacitidine and Venetoclax Combination for Upfront Treatment of Higher-Risk Myelodysplastic Syndromes
Published date:
09/01/2021
Excerpt:
Among pts with ASXL1 SM, the CR rate was 47% compared to 9% for aza alone (p <.005)….Aza/ven combination is associated with higher responses overall and among ASXL-1 SM higher-risk MDS pts and encouraging early data support aza/ven as a bridge to AHSCT, with 90% 2-year OS.
Source:
Title:
ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine
Published date:
09/21/2021
Excerpt:
As DNMT inhibitors show efficacy in MDS/AML...Further treatment of the ASXL1 mutant and corrected cells with the combination treatment of VEN and AZA demonstrated significantly decreased cell viability of the ASXL1 mutant cells compared to the corrected cells, consistent with the proliferation assays conducted with VEN and AZA alone.
DOI:
https://doi.org/10.1038/s41408-021-00541-0
